Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > COMMENTARY
COMMENTARY
-
5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
September 29, 2021
-
CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
August 3, 2021
-
Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
-
Updated Heart Failure Guidelines Position Entresto, SGLT2 Inhibitors as New Treatment Strategy Options
June 22, 2021
-
Battle Looming over 2% Adjustment Rate as New Honebuto Paper Nears Completion
June 1, 2021
-
Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
February 9, 2021
-
Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
January 8, 2021
-
Japan Rushing to Build COVID-19 Vaccination Regime as 1st Approval Draws Near
December 28, 2020
-
Generic Makers Reorganizing Manufacturing Sites; Leveraging Their Strengths to Survive
October 23, 2020
-
IPOs or Sale? Employee Motivation Depends on Exit Strategies of Investment Funds
September 16, 2020
-
Sumitomo Dainippon Aims at 100 Billion Yen Sales from “Frontier Business,” Making Challenge Beyond Drugs
September 9, 2020
-
COVID-19 Pandemic to Test True Value of MHLW’s Officers with Medical/Pharma Backgrounds
August 26, 2020
-
COVID-19’s Impact on Pharma Becoming Clearer with New Data, Earnings
August 17, 2020
-
With Equivocal Honebuto Wording, Off-Year Re-Pricing Debate Delayed Until Year-End
July 30, 2020
-
Japan to See Arrival of 1st Treatment for HFpEF, Will Entresto Meet Unmet Medical Needs?
July 22, 2020
-
Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
July 13, 2020
-
Will Zolgensma Delay Spur Revision of Sakigake Designation System?
June 11, 2020
-
Establish Development Regime to Always Be Prepared for New Infectious Disease, Global Health Confab Urges amid COVID-19
May 7, 2020
-
Blurred Outlook for Off-Year Drug Re-Pricing, Will Japan Go Ahead with April 2021 Plan?
April 27, 2020
-
Drug Rep Number Might Have Logged 5,000-Plus Decrease in 1 Year: Jiho Tally
April 22, 2020
ページ
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…